Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. BioPharma Credit's selling, general, & admin. expense for the
six
months ended in Dec. 2025 was $1.2 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was $2.3 Mil.
BioPharma Credit (LSE:BPCR) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
BioPharma Credit Selling, General, & Admin. Expense Related Terms
BioPharma Credit Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit Selling, General, & Admin. Expense Chart
LSE:BPCR vs BLK, BX, KKR: Selling, General, & Admin. Expense Comparison
For the Asset Management subindustry, BioPharma Credit's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit Selling, General, & Admin. Expense vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's Selling, General, & Admin. Expense falls into.
BioPharma Credit Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of $2.3 Mil mean?
BioPharma Credit (LSE:BPCR) has a Selling, General, & Admin. Expense of $2.3 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on BioPharma Credit and its competitors.
Is BioPharma Credit's Selling, General, & Admin. Expense too high?
BioPharma Credit's current Selling, General, & Admin. Expense is $2.3 Mil. Overall, BioPharma Credit has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Selling, General, & Admin. Expense compare to BLK and BX?
BioPharma Credit's Selling, General, & Admin. Expense of $2.3 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for an Asset Management company?
A good Selling, General, & Admin. Expense depends on the Asset Management industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on BioPharma Credit and its competitors. BioPharma Credit's current Selling, General, & Admin. Expense is $2.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.96 — trading right at its estimated fair value. The current Selling, General, & Admin. Expense is $2.3 Mil. BioPharma Credit's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Selling, General, & Admin. Expense is $2.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued.
The current stock price of $0.96 is trading 0% below its estimated GF Value™ of $0.96.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
Selling, General, & Admin. Expense: $2.3 Mil
GF Value™: $0.96 vs. price of $0.96 (0% below fair value)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
52GF Score
Get the complete analysis for LSE:BPCR
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
